Should the patent system for new medicines be abolished?
dc.contributor.author | DiMasi, JA | |
dc.contributor.author | Grabowski, HG | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2013-04-23T16:54:45Z | |
dc.date.issued | 2007-11 | |
dc.identifier | ||
dc.identifier | 6100393 | |
dc.identifier.eissn | 1532-6535 | |
dc.identifier.uri | ||
dc.language | eng | |
dc.publisher | Springer Science and Business Media LLC | |
dc.relation.ispartof | Clin Pharmacol Ther | |
dc.relation.isversionof | 10.1038/sj.clpt.6100393 | |
dc.subject | Biomedical Research | |
dc.subject | Commerce | |
dc.subject | Cost-Benefit Analysis | |
dc.subject | Drug Costs | |
dc.subject | Drug Industry | |
dc.subject | Financing, Government | |
dc.subject | Humans | |
dc.subject | Insurance Coverage | |
dc.subject | Legislation, Drug | |
dc.subject | Orphan Drug Production | |
dc.subject | Patents as Topic | |
dc.subject | Pharmaceutical Preparations | |
dc.subject | Public Policy | |
dc.subject | United States | |
dc.title | Should the patent system for new medicines be abolished? | |
dc.type | Journal article | |
pubs.author-url | ||
pubs.begin-page | 488 | |
pubs.end-page | 490 | |
pubs.issue | 5 | |
pubs.organisational-group | Duke | |
pubs.organisational-group | Economics | |
pubs.organisational-group | Trinity College of Arts & Sciences | |
pubs.publication-status | Published | |
pubs.volume | 82 |
Files
Original bundle
1 - 1 of 1